ZOETIS INC's ticker is ZTS and the CUSIP is 98978V103. A total of 1,490 filers reported holding ZOETIS INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
About ZOETIS INC
Zoetis Inc. is a leading animal health company that specializes in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines. The company was founded in 2013 and is headquartered in Parsippany, New Jersey. Zoetis operates in more than 100 countries and has a diverse portfolio of products that cater to the needs of livestock and companion animals.
Zoetis has a strong leadership team, with Kristin Peck serving as the CEO and Juan Ramón Alaix as the Executive Chairman of the Board. The company has a robust research and development program, with a focus on innovation and sustainability. Zoetis has made significant investments in digital technologies, which have helped the company to improve its operational efficiency and enhance customer experience.
Zoetis has a strong financial position, with a market capitalization of over $80 billion. The company has consistently delivered strong financial results, with revenue of $6.3 billion in 2020, up 6% from the previous year. Zoetis has a diversified revenue stream, with products for livestock accounting for 70% of its revenue and products for companion animals accounting for the remaining 30%.
In conclusion, Zoetis is a leading animal health company with a strong leadership team, a robust research and development program, and a diversified portfolio of products. The company has a strong financial position and has consistently delivered strong financial results. Zoetis is well-positioned to capitalize on the growing demand for animal health products and is a solid investment option for stock market investors.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,040,665 | +196.7% | 6,043 | +186.8% | 0.00% | +300.0% |
| Q1 2023 | $350,689 | -77.4% | 2,107 | -79.9% | 0.00% | -83.3% |
| Q3 2022 | $1,551,000 | +0.6% | 10,462 | +65.7% | 0.01% | 0.0% |
| Q4 2021 | $1,541,000 | -5.2% | 6,314 | -38.8% | 0.01% | -25.0% |
| Q1 2021 | $1,626,000 | -32.6% | 10,324 | -41.4% | 0.01% | -42.9% |
| Q2 2020 | $2,414,000 | – | 17,614 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BANK PICTET & CIE (ASIA) LTD | 132,900 | $24,767,000 | 6.94% |
| LOUNTZIS ASSET MANAGEMENT, LLC | 55,834 | $10,404,000 | 6.34% |
| Raub Brock Capital Management LP | 159,983 | $29,814,000 | 5.14% |
| Ako Capital | 2,432,203 | $453,265,000 | 5.11% |
| Bristol Gate Capital Partners Inc. | 516,909 | $96,332,000 | 5.05% |
| Milestone Resources Group Ltd | 458,237 | $85,397,000 | 4.79% |
| Stonehage Fleming Financial Services Holdings Ltd | 854,215 | $159,282,000 | 4.65% |
| Intermede Investment Partners Ltd | 1,093,254 | $203,739,000 | 4.63% |
| BANQUE PICTET & CIE SA | 2,055,177 | $383,003,000 | 4.27% |
| Polen Capital Management | 11,907,759 | $2,219,130,000 | 4.25% |